Recovery and Safety Profiles of Marrow and PBSC Donors: Experience of the National Marrow Donor Program John P. Miller, Elizabeth H. Perry, Thomas H.

Slides:

Advertisements

Similar presentations

A Simplified Procedure for Hematopoietic Stem Cell Amplification Using a Serum-Free, Feeder Cell-Free Culture System Ian M. Rogers, Nobuko Yamanaka, Robert.

Advertisements

Find the lower and upper quartiles for the data set.

Alexander H. Schmidt, Thilo Mengling, Camila J

Reduced Frequency of Regulatory T Cells in Peripheral Blood Stem Cell Compared to Bone Marrow Transplantations Céline Blache, Joe-Marc Chauvin, Aude.

Related PBSC Donors Age >60 Have High Rates of Baseline and Donation-Related Pain and Slow Recovery: First Report from the Related Donor Safety Study.

How to Treat MDS without Stem Cell Transplantation

The Effect of Statin Use at the Time of Autologous Transplant on Response and Survival in Multiple Myeloma Mehdi Hamadani, Erinn Hade, Don M. Benson,

Adverse events among 2408 unrelated donors of peripheral blood stem cells: results of a prospective trial from the National Marrow Donor Program by Michael.

The Effect of the Composition of Unrelated Donor Bone Marrow and Peripheral Blood Progenitor Cell Grafts on Transplantation Outcomes Nancy H. Collins,

Increased Levels of Tumor Necrosis Factor α Are Associated with an Increased Risk of Cytomegalovirus Infection after Allogeneic Hematopoietic Stem Cell.

Vaccination of Children following Allogeneic Stem Cell Transplantation

Peter Hurley, Suma Konety, Qing Cao, Daniel Weisdorf, Anne Blaes

Randomized Phase III Trial of Pegfilgrastim versus Filgrastim after Autologus Peripheral Blood Stem Cell Transplantation Aaron Gerds, Mary Fox-Geiman,

Influence of Stem Cell Source on Outcomes of Allogeneic Reduced-Intensity Conditioning Therapy Transplants Using Haploidentical Related Donors Kenneth.

Allogeneic Stem Cell Transplantation in Myelofibrosis

Cost and Clinical Analysis of Autologous Hematopoietic Stem Cell Mobilization with G- CSF and Plerixafor Compared to G-CSF and Cyclophosphamide Paul Shaughnessy,

Ex vivo expansion of megakaryocyte precursors from umbilical cord blood CD34+ cells in a closed liquid culture system Peter H. Shaw, Devin Gilligan,

Pain, Donation-Related Symptoms and the Trajectory of Recovery in Children after Bone Marrow (BM) Donation Are Influenced By Age (Pre vs. Post-Puberty)

Basal CD34+ Cell Count Predicts Peripheral Blood Stem Cell Mobilization in Healthy Donors after Administration of Granulocyte Colony–Stimulating Factor:

Twenty Years of Unrelated Donor Hematopoietic Cell Transplantation for Adult Recipients Facilitated by the National Marrow Donor Program Chatchada Karanes,

Related PBSC Donors Experience Higher Levels of Pain and Donation-Related Symptoms and Less Complete Rates of Recovery Compared to Unrelated Donors:

Sabina Kersting, Leo F. Verdonck

Bisphosphonate Therapy for Reduced Bone Mineral Density in Children with Chronic Graft-versus-Host Disease Paul A. Carpenter, Paul Hoffmeister, Charles.

Carbon Monoxide Diffusion Capacity: How Low Can You Go for Hematopoietic Cell Transplantation Eligibility? Jason W. Chien, Keith M. Sullivan Biology.

Peripheral Blood Grafts from Unrelated Donors Are Associated with Increased Acute and Chronic Graft-versus-Host Disease without Improved Survival Mary.

Immune Reconstitution Kinetics as an Early Predictor for Mortality using Various Hematopoietic Stem Cell Sources in Children Imke Heleen Bartelink, Svetlana.

Motivations, Experiences, and Perspectives of Bone Marrow and Peripheral Blood Stem Cell Donors: Thematic Synthesis of Qualitative Studies Maria C. Garcia,

Graft Transit Time Has No Effect on Outcome of Unrelated Donor Hematopoietic Cell Transplants Performed in Australia and New Zealand: A Study from the.

A Process to Facilitate Decision Making in Pediatric Stem Cell Transplantation: The Individualized Care Planning and Coordination Model Justin N. Baker,

A Pilot, Exploratory, Randomized, Phase II Safety Study Evaluating Tumor Cell Mobilization and Apheresis Product Contamination in Patients Treated with.

Twenty Years of Unrelated Donor Bone Marrow Transplantation for Pediatric Acute Leukemia Facilitated by the National Marrow Donor Program Margaret L.

Hepatic Safety of Voriconazole after Allogeneic Hematopoietic Stem Cell Transplantation I. Amigues, N. Cohen, D. Chung, S.K. Seo, C. Plescia, A. Jakubowski,

Significant Improvement in Survival after Unrelated Donor Hematopoietic Cell Transplantation in the Recent Era Navneet S. Majhail, Pintip Chitphakdithai,

Chronic Kidney Dysfunction in Patients Alive without Relapse 2 Years after Allogeneic Hematopoietic Stem Cell Transplantation Imad Abboud, Raphaël Porcher,

Plerixafor Plus Granulocyte Colony-Stimulating Factor versus Placebo Plus Granulocyte Colony-Stimulating Factor for Mobilization of CD34+ Hematopoietic.

Correlation between the numbers of naive T cells infused with blood stem cell allografts and the counts of naive T cells after transplantation Jan Storek,

Effect of Total Nucleated and CD34+ Cell Dose on Outcome after Allogeneic Hematopoietic Stem Cell Transplantation Mats Remberger, Johan Törlén, Olle.

B Cells and Transplantation: An Educational Resource

High White Blood Cell Concentration in the Peripheral Blood Stem Cell Product Can Induce Seizures during Infusion of Autologous Peripheral Blood Stem.

Recovery of Unrelated Donors of Peripheral Blood Stem Cells versus Recovery of Unrelated Donors of Bone Marrow: A Prespecified Analysis from the Phase.

Mobilization of Hematopoietic Stem Cells with Lenograstim in Healthy Donors: Efficacy and Safety Analysis According to Donor Age Massimo Martino, Erminio.

Pharmacokinetic Evaluation of the Drug Interaction between Intravenous Itraconazole and Intravenous Tacrolimus or Intravenous Cyclosporin A in Allogeneic.

Predonation Health-Related Quality of Life Scores Predict Time to Recovery in Hematopoietic Stem Cell Donors Annelies Billen, J. Alejandro Madrigal,

Allogeneic Stem Cell Transplantation for Aplastic Anemia

Biology of Blood and Marrow Transplantation

Adverse Prognostic Factors for Morbidity and Mortality During Peripheral Blood Stem Cell Mobilization in Patients with Light Chain Amyloidosis Jason.

Race and Ethnicity Influences Collection of Granulocyte Colony–Stimulating Factor– Mobilized Peripheral Blood Progenitor Cells from Unrelated Donors, a.

Regression Models for Hazard Rates Versus Cumulative Incidence Probabilities in Hematopoietic Cell Transplantation Data Brent R. Logan, Mei-Jie Zhang,

Tbo-Filgrastim versus Filgrastim during Mobilization and Neutrophil Engraftment for Autologous Stem Cell Transplantation Mohammed M. Elayan, Justin G.

What is quality in a transplant program?

Central Nervous System Complications after Allogeneic Hematopoietic Stem Cell Transplantation: Incidence, Manifestations, and Clinical Significance Deborah.

Karen K. Ballen, Roberta J. King, Pintip Chitphakdithai, Charles D

Chimeric Antigen Receptor–Modified T Cells: Clinical Translation in Stem Cell Transplantation and Beyond Stanley R. Riddell, Michael C. Jensen, Carl.

HLA-Allele Matched Unrelated Donors Compared to HLA-Matched Sibling Donors: Role of Cell Source and Disease Risk Category Ann Woolfrey, Stephanie J.

Blood and Marrow Transplant Handbook

Donation Activities and Product Integrity in Unrelated Donor Allogeneic Hematopoietic Transplantation: Experience of the National Marrow Donor Program

Reticulocyte Maturation Parameters Are Reliable Early Predictors of Hematopoietic Engraftment after Allogeneic Stem Cell Transplantation J.R. Molina,

Varicella-Zoster Virus Disease Is More Frequent after Cord Blood Than after Bone Marrow Transplantation Kristel Vandenbosch, Philippe Ovetchkine, Martin.

Mammen Chandy Biology of Blood and Marrow Transplantation

Acute toxicities of unrelated bone marrow versus peripheral blood stem cell donation: results of a prospective trial from the National Marrow Donor Program.

Treatment versus Transplant for Challenging Hematologic Disorders

Prospective Monitoring of Tumor Necrosis Factor α and Interferon γ to Predict the Onset of Acute and Chronic Graft-versus-Host Disease after Allogeneic.

Pain. Pain. (A) Skeletal pain experienced by bone marrow (BM) and peripheral blood stem cell (PBSC) donors at baseline, during the pericollection period,

Adult Recipients of Matched Related Donor Blood Cell Transplants Given Myeloablative Regimens Including Pretransplant Antithymocyte Globulin Have Lower.

Mary Eapen Biology of Blood and Marrow Transplantation

Futility of Relapsed Diffuse Large B Cell Lymphoma Transplantation?

In Memoriam: E. Donnall Thomas

Optimal Donor Selection: Beyond HLA

Donor Experiences of Second Marrow or Peripheral Blood Stem Cell Collection Mirror the First, but CD34+ Yields Are Less David F. Stroncek, Bronwen E.

Andrew R. Rezvani, Barry E. Storer, Katherine A. Guthrie, H

Presentation transcript:

Recovery and Safety Profiles of Marrow and PBSC Donors: Experience of the National Marrow Donor Program John P. Miller, Elizabeth H. Perry, Thomas H. Price, Charles D. Bolan, Chatchada Karanes, Theresa M. Boyd, Pintip Chitphakdithai, Roberta J. King Biology of Blood and Marrow Transplantation Volume 14, Issue 9, Pages 29-36 (September 2008) DOI: 10.1016/j.bbmt.2008.05.018 Copyright © 2008 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 1 (A) Percentage of BM donors reporting pain at selected sites over time. Reports of pain and pain severity were collected at the indicated time points post-donation. Throat pain is largely restricted to donors receiving general anesthesia, whereas headache is more common in donors receiving regional anesthesia, for example, epidural. (B) Six most frequently reported body symptoms experienced by BM donors at the indicated time points post-donation. Biology of Blood and Marrow Transplantation 2008 14, 29-36DOI: (10.1016/j.bbmt.2008.05.018) Copyright © 2008 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 2 (A) Percentage of PBSC donors reporting bone pain over time. Reports of bone pain and severity of pain were collected at the indicated time points during mobilization, collection, and post-donation. Day 1 is the first day of filgrastim administration; day 5 is the first day of apheresis. Bone pain represents pain in at least one of the following sites: general bone pain, back, head, limb, joint, hip, and neck. The severity of bone pain is defined as the maximum grade among these pain sites. (B) Six most frequently reported body symptoms experienced by PBSC donors during mobilization and collection, and at the indicated time points post-donation. The percentages for day 1 to day 6 represent the frequencies of the highest grade of symptoms during mobilization and collection. Biology of Blood and Marrow Transplantation 2008 14, 29-36DOI: (10.1016/j.bbmt.2008.05.018) Copyright © 2008 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 3 Box and whiskers plot of BM donor hemoglobin levels showing the maximum, upper quartile, median, lower quartile, and minimum values at baseline, the day of collection, and the indicated time points post-donation. Biology of Blood and Marrow Transplantation 2008 14, 29-36DOI: (10.1016/j.bbmt.2008.05.018) Copyright © 2008 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 4 (A) Box and whiskers plot of PBSC donor WBC counts showing the maximum, upper quartile, median, lower quartile, and minimum values at the indicated time points during mobilization, collection, and post-donation. (B) Box and whiskers plot of PBSC donor platelet counts showing the maximum, upper quartile, median, lower quartile, and minimum values at the indicated time points during mobilization, collection, and post-donation. (C) Box and whiskers plot of PBSC donor hemoglobin levels showing the maximum, upper quartile, median, lower quartile, and minimum values at the indicated time points during mobilization, collection, and post-donation. (Day 1 is the first day of filgrastim administration; day 5 is the first day of apheresis; pre and post refer to the apheresis procedure.) Biology of Blood and Marrow Transplantation 2008 14, 29-36DOI: (10.1016/j.bbmt.2008.05.018) Copyright © 2008 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 5 Kaplan-Meier plots of time to recovery from stem cell donation (first donations performed from November 2001 through March 2006). Biology of Blood and Marrow Transplantation 2008 14, 29-36DOI: (10.1016/j.bbmt.2008.05.018) Copyright © 2008 American Society for Blood and Marrow Transplantation Terms and Conditions